Patients with rosacea make significantly more insurance claims and are more likely to access their treatment prescriptions compared with patients with melasma, researchers reported in a study published in the British Journal of Dermatology.

The study authors retrospectively assessed the rate of insurance coverage for first-line topical treatments for rosacea compared with melasma. They used data from a commercial database from 2016 to 2018, which included health insurance claims and enrollment data from large employers and health plans in the United States that provide private health care for more than 43.4 million people.

Read the full article at